Ureylene phenylene anionic naphthalene-sulfonic acids, their use as complement system inhibitors in a body fluid and process for their preparation
申请人:AMERICAN CYANAMID COMPANY
公开号:EP0008154A1
公开(公告)日:1980-02-20
The present invention provides novel ureylene phenylene anionic naphthalenesulfonic acids, which have complement-inhibiting properties and which may be represented by the general formula:
wherein X and Y are each selected from the group consisting of -CO- and -SO2-; R and R3 are each selected from the group consisting of hydrogen, methyl and -S03A, wherein A is a pharmaceutically acceptable salt cation; R, and R4 are each selected from the group consisting of hydrogen and -COOB. wherein B is selected from the group consisting of hydrogen and a pharmaceutically acceptable salt cation; R2 and Rs are each selected from the group consisting of hydrogen and methyl; with the proviso that R. R,, R2, R3, R4 and R5 may not all be hydrogen; with the second proviso that when X and Y are both -CO- and R2 is methyl, then R, R,, R3, R. and Rs may not all be hydrogen; and with the third proviso that no phenyl moiety can contain both -SO3A and -COOB.
The corresponding amine compounds of the formula below are novel intermediates for the novelureylene compounds above:
本发明提供了具有补体抑制特性的新型脲苯基阴离子萘磺酸,其可由通式表示:
其中 X 和 Y 各自选自由 -CO- 和 -SO2- 组成的组;R 和 R3 各自选自由氢、甲基和 -S03A 组成的组,其中 A 是药学上可接受的阳离子盐;R 和 R4 各自选自由氢和 -COOB 组成的组。其中 B 选自氢和药学上可接受的盐阳离子组成的组;R2 和 Rs 各选自氢和甲基组成的组;但书中 R、R、R2、R3、R4 和 R5 不一定都是氢;第二个但书是当 X 和 Y 都是-CO-且 R2 是甲基时,则 R、R、R3、R.和 Rs 不一定都是氢;第三个但书是任何苯基都不能同时含有-SO3A 和-COOB。
下式中相应的胺化合物是上述新脲烯类化合物的新型中间体:
Neue Sulfonylazole
申请人:NIHON TOKUSHU NOYAKU SEIZO K.K.
公开号:EP0237912A1
公开(公告)日:1987-09-23
Sulfonylazole der Formel (I)
in der
X Wasserstoff, Alkyl, Halogen, Alkoxy oder Aryl bezeichnet,
Y Wasserstoff, Alkyl, Halogen, Nitro oder Alkoxy bezeichnet,
Z Wasserstoff, Alkyl, Halogen oder Alkoxy bezeichnet oder
Y und Z zusammen einen gegebenenfalls substituierten cyclischen Ring bezeichnen, der Hetero-Atome enthalten kann, wurden gefunden und ihre Wirkung als Fungizide im Pflanzenschutz.
Die neuen Sulfonylazole der FormeL (I) können aus geeigneten substituierten Phenylsulfonylhalogeniden mit geeigneten Heterocyclen in Gegenwart eines inerten Lösungsmittels hergestellt werden.
式(I)的磺酰唑
其中
X 表示氢、烷基、卤素、烷氧基或芳基、
Y 表示氢、烷基、卤素、硝基或烷氧基、
Z 表示氢、烷基、卤素或烷氧基,或
Y 和 Z 共同表示任选取代的环,其中可能含有杂原子。
FormeL(I)的新型磺酰唑可以在惰性溶剂存在下,由合适的取代苯磺酰卤与合适的杂环制备而成。
Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR
作者:Jackie D. Kendall、Anna C. Giddens、Kit Yee Tsang、Raphaël Frédérick、Elaine S. Marshall、Ripudaman Singh、Claire L. Lill、Woo-Jeong Lee、Sharada Kolekar、Mindy Chao、Alisha Malik、Shuqiao Yu、Claire Chaussade、Christina Buchanan、Gordon W. Rewcastle、Bruce C. Baguley、Jack U. Flanagan、Stephen M.F. Jamieson、William A. Denny、Peter R. Shepherd
DOI:10.1016/j.bmc.2011.11.031
日期:2012.1
Structure-activity relationship studies of the pyrazolo[1,5-a]pyridine class of PI3 kinase inhibitors show that substitution off the hydrazone nitrogen and replacement of the sulfonyl both gave a loss of p110 alpha selectivity, with the exception of an N-hydroxyethyl analogue. Limited substitutions were tolerated around the phenyl ring; in particular the 2,5-substitution pattern was important for PI3 kinase activity. The N-hydroxyethyl compound also showed good inhibition of cell proliferation and inhibition of phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity. It had suitable pharmacokinetics for evaluation in vivo, and showed tumour growth inhibition in two human tumour cell lines in xenograft studies. This work has provided suggestions for the design of more soluble analogues. (C) 2011 Elsevier Ltd. All rights reserved.